Duchenne muscular dystrophy

Keros Therapeutics has dosed the first patient in a Phase 2 clinical trial of rinvatercept, an investigational therapy for Duchenne muscular dystrophy. The milestone marks the start of patient enrollment in the study, a key step in testing whether the drug can benefit people with the progressive muscle-wasting disease. Details on trial sites and timelines have not been widely reported yet.